Phase I/II Trial of MEK Inhibitor MEK162 in Patients with Relapsed and or Refractory Acute Myeloid Leukemia and Patients with Poor Prognosis Acute Myeloid Leukemia Not Suitable for or Unwilling to Receive Standard Therapy.
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of MEK162 that can be given to patients with advanced leukemia.
Disease Group: Leukemia
Treatment Agent: MEK162
Treatment Location: Only at MD Anderson
IRB Review and Approval Date: 08/27/2014
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
Phase I/Phase II
For general questions about clinical trials: